Meningococcal infection in Moscow: a ten-year observation (2014–2023)


DOI: https://dx.doi.org/10.18565/epidem.2024.14.3.30-6

Koroleva I.S., Gritsay M.I., Koroleva M.A., Churilova N.S., Beloshitsky G.V., Kobzeva Yu.V., Vasilevskaya D.Yu.

1) Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being, Moscow, Russia; 2) Moscow Office of Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being, Moscow, Russia
Background. Attention to meningococcal infection (MI) continues unabated. The unique features of the disease are diverse, and some manifestations are extremely dangerous. In 2017, representatives of governments, global health organizations, public health authorities, academia, the private sector, and civil society called for combating meningococcal meningitis as a public health threat.
Objective. Characteristics of modern epidemic manifestations of MI in Moscow.
Materials and methods. An analysis of MI cases registered in Moscow from 2014 to 2023 and the results of studies of biomaterial from patients with the generalized MI forms was performed.
Results. A trend of increasing MI incidence in long-term dynamics with active change of serogroup landscape was revealed. Higher incidence among young people was established.
Conclusion. In order to strengthen population immunity, it is necessary to expand the regional vaccination calendar for additional vaccination of students of general education organizations from the 3rd to the 11th grade; first-year students of professional educational organizations and higher educational institutions.

Literature


1. European Centre for Disease Prevention and Control. Surveillance Atlas of Infectious Diseases. https://atlas.ecdc.europa.eu/public/ index.aspx


2. Public Health Agency of Canada. Notifiable Disease Charts. https://diseases.canada.ca/notifiable/charts-list


3. Centers for Disease Control and Prevention. Enhanced Meningococcal Disease Surveillance Reports. https://www.cdc.gov/meningococcal/surveillance/ index.html#enhanced-reports


4. New Zealand Ministry of Health. Meningococcal Disease Reports. https://surv.esr.cri.nz/surveillance/Meningococcal_disease


5. Thompson M.J., Ninis N., Perera R., Mayon-White R., Phillips C., Bailey L. et al. Clinical recognition of meningococcal disease in children and adolescents. Lancet 2006; 367: 397–403. DOI: 10.1016/S0140-6736(06)67932-4


6. Beebeejaun K., Parikh S.R., Campbell H., Gray S., Borrow R., Ramsay M.E. et al. Invasive meningococcal disease: Timing and cause of death in England, 2008–2015. J. Infect. 2020; 80(3): 286–90. DOI: 10.1016/j.jinf.2019.12.008


7. Wang B., Santoreneos R., Giles L., Afzali H.H.A., Marshall H. Case fatality rates of invasive meningococcal disease by serogroup and age: A systematic review and meta-analysis. Vaccine 2019; 37(21): 2768–82. DOI: 10.1016/ j.vaccine.2019.04.020


8. Deghmane A.E., Taha S., Taha M.K. Global epidemiology and changing clinical presentations of invasive meningococcal disease: a narrative review. Infect. Dis. (Lond.) 2022; 54(1): 1–7. DOI: 10.1080/23744235.2021.1971289


9. Olbrich K.J., Müller D., Schumacher S., Beck E., Koerber E. Systematic Review of Invasive Meningococcal Disease: Sequelae and Quality of Life Impact on Patients and Their Caregivers. Infect. Dis. Ther. 2018; 7: 421–38. DOI: 10.1007/s40121-018-0213-2


10. Koomen I., Raat H., Jennekens-Schinkel A., Grobbee D.E., Roord J.J., Roord J.J. et al. Academic and behavioral limitations and health-related quality of life in school age survivors of bacterial meningitis. Qual. Life Res. 2005; 14(6): 1563–72. DOI: 10.1007/s11136-004-7706-z


11. Christensen H., May M., Bowen L., Hickman V., Trotter C.L Meningococcal carriage by age: a systematic review and meta-analysis. Lancet Infect. Dis. 2010; 10(12): 853–61. DOI: 10.1016/S1473-3099(10)70251-6


12. Wright C., Wordsworth R., Glennie L. Counting the Cost of Meningococcal Disease Scenarios of Severe Meningitis and Septicemia. Pediatr. Drugs. Paediatr Drugs. 2013;15(1): 49–58. DOI: 10.1007/s40272-012-0006-0


13. Darbà J., Kaskens L., Hark M., Wright C. Costs of surviving meningococcal disease in Spain: Evaluation for two cases of severe meningitis and septicaemia. Vaccine 2014; 32: 5006–12. DOI: 10.1016/j.vaccine.2014.07.019


14. World Health Organization. Defeating meningitis by 2030: a global road map. https://iris.who.int/bitstream/handle/10665/342010/9789240026407eng.pdf? sequence=1


15. Лабораторная диагностика менингококковой инфекции и гнойных бактериальных менингитов: Методические указания МУК 4.2.1887-04. М., 2005.


[Laboratory diagnosis of meningococcal infection and purulent bacterial meningitis: Methodological guidelines of MUC 4.2.1887-04]. Moscow, 2005. (In Russ.).


16. Meningococcal vaccines: WHO position paper, November 2011. Wkly Epidemiol. Rec. 2011; 86(47): 521–39. who-position-paper-on-meningococca-vaccine.pdf


17. Лыткина И.Н., Чистякова Г.Г., Королева И.С. Профилактика бактериальных гнойных менингитов у детей в Москве. Новости вакцинопрофилактики. Вакцинация. Информационный бюллетень 1999; (2): 1–11.


Lytkina I.N., Chistyakova G.G., Koroleva I.S. [Prevention of bacterial purulent meningitis in children in Moscow]. Vaccine prevention news. Vaccination. Information Bulletin 1999; (2): 1–11. (In Russ.).


18. Booy R., Gentile A., Nissen M., Whelan J., Abitbo V. Recent changes in the epidemiology of Neisseria meningitidis serogroup W across the world, current vaccination policy choices and possible future strategies. Hum. Vaccin Immunother. 2019; 15(2): 470–80. DOI: 10.1080/21645515. 2018.1532248


19. Potts C.C., Retchless A.C., McNamara L.A., Marasini D., Reese N., Swint S. et al. Acquisition of ciprofloxacin resistance among an expanding clade of β-lactamase– positive, serogroup Y Neisseria meningitidis in the United States. Clin. Infect. Dis. 2021; 73(7): 1185–93. DOI: 10.1093/cid/ ciab358


20. Ladhani S.N., Lucidarme J., Parikh S.R., Campbell Н., Borrow R., Ramsay M.E. et al. Meningococcal disease and sexual transmission: urogenital and anorectal infections and invasive disease due to Neisseria meningitidis. Lancet 2020; 395(10240): 1865–77. DOI: 10.1016/S0140-6736(20)30913-2


21. Костюкова Н.Н., Бехало В.А., Чернышова Т.Ф. Менингококковая инфекция в Российской Федерации: прошлое и ближайшие перспективы. Эпидемиол. инфекц. болезни. Актуал. вопр. 2014; (2): 73–9.


Kostyukova N.N., Behal/o V.A., Chernyshova T.F. [Meningococcal infection in the Russian Federation: past and immediate prospects]. Epidemiology and infectious diseases. Сurrent items 2014; (2): 73–9. (In Russ.).


About the Autors


Irina S. Koroleva, МD, Head, Laboratory for Epidemiology of Meningococcal Infection and Purulent Bacterial Meningitis, Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being, Moscow, Russia; irina-korol@yandex.ru; https://orcid.org/0000-0003-0578-146X
Maria I. Gritsay, Cand. Med. Sci., Researcher, Laboratory for Epidemiology of Meningococcal Infection and Purulent Bacterial Meningitis, Central Research Institute of Epidemiology, Federal Service for Surveillance on Consumer Rights Protection and Human Well-Being, Moscow, Russia; maria-griz@mail.ru; https://orcid.org/0000-0002-6288-9074.
Maria А. Koroleva, МD, Senior Researcher, Laboratory for Epidemiology of Meningococcal Infection and Purulent Bacterial Meningitis, Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being, Moscow, Russia; korolevamaria389@mail.ru; https://orcid.org/0000-0002-2714-1191.
Nadejda S. Churilova, Junior Researcher, Laboratory for Epidemiology of Meningococcal Infection and Purulent Bacterial Meningitis, Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being, Moscow, Russia; n27101996@yandex.ru; https://orcid.org/0000-0001-5344-5829.
Grigoriy V. Beloshitsky, Cand. Med. Sci., Senior Researcher, Laboratory for Epidemiology of Meningococcal Infection and Purulent Bacterial Meningitis, Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being, Moscow, Russia; g-belosh1@yandex.ru; https://orcid.org/0000-0002-4769-3890
Yulia V. Kobzeva, Head, Epidemiological Surveillance Department, Moscow Office of Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being, Moscow, Russia; epid_otdel@mail.ru
Daria Yu. Vasilevskaya, Deputy Head, Epidemiological Surveillance Department, Moscow Office of Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being, Moscow, Russia; epid_otdel@mail.ru


Similar Articles


Бионика Медиа